Payment overview · 2025
General Payments
$282.59
16 reported records · 7 companies
Healthcare provider profile · identity verified
Mary E Bundle, PAC
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · RICHLANDS, NC · NPI 1073598686
Verified facts
What the public records show
CMS Open Payments records show Mary E Bundle, PAC received $282.59 in general payments during 2025 across 16 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $75.24 | 26.6% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $72.69 | 25.7% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $64.07 | 22.7% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.11 | 8.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.45 | 5.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.29 | 5.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.74 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $282.59 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $56.40 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $50.59 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $40.90 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.34 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.89 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.11 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
79 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 464 | 116 |
| Lisinopril | Lisinopril | 285 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 255 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 232 | 66 |
| Omeprazole | Omeprazole | 174 | 53 |
| Gabapentin | Gabapentin | 167 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 152 | 42 |
| Metformin Hcl Er | Metformin Hcl | 151 | 44 |
| Furosemide | Furosemide | 130 | 37 |
| Sertraline Hcl | Sertraline Hcl | 128 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 124 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 50 |
| Famotidine | Famotidine | 117 | 23 |
| Losartan Potassium | Losartan Potassium | 101 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 101 | 31 |
| Potassium Chloride | Potassium Chloride | 99 | 25 |
| Montelukast Sodium | Montelukast Sodium | 93 | 21 |
| Metformin Hcl | Metformin Hcl | 82 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 15 |
| Trazodone Hcl | Trazodone Hcl | 74 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 69 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 16 |
| Simvastatin | Simvastatin | 62 | 17 |
| Eliquis | Apixaban | 59 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 15 |
| Nystatin | Nystatin | 57 | 18 |
| Valsartan | Valsartan | 55 | 18 |
| Carvedilol | Carvedilol | 54 | 16 |
| Ozempic | Semaglutide | 54 | suppressed |
| Cephalexin | Cephalexin | 53 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 12 |
| Prednisone | Prednisone | 51 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 50 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 16 |
| Alendronate Sodium | Alendronate Sodium | 44 | 12 |
| Cefdinir | Cefdinir | 44 | 38 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 13 |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 38 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 37 | suppressed |
| Glipizide | Glipizide | 35 | suppressed |
| Allopurinol | Allopurinol | 34 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 14 |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 27 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | 11 |
| Meclizine Hcl | Meclizine Hcl | 21 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 12 |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 11 | suppressed |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $282.59 · 16 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, OTEZLA, REPATHA, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, Wegovy, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error